NovoCure Capital Expenditures (CapEx) Growth & History (NVCR)
NovoCure's capital expenditures (capex) was $26.6M for fiscal 2025.
View full NovoCure company overviewNovoCure annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $26.6M | −$16.2M | −37.82% |
| 2024 | 2024-12-31 | $42.9M | $15.8M | +58.18% |
| 2023 | 2023-12-31 | $27.1M | $5.7M | +26.85% |
| 2022 | 2022-12-31 | $21.4M | −$2.8M | −11.63% |
| 2021 | 2021-12-31 | $24.2M | $9.2M | +61.48% |
| 2020 | 2020-12-31 | $15.0M | $4.5M | +42.76% |
| 2019 | 2019-12-31 | $10.5M | $3.8M | +56.24% |
| 2018 | 2018-12-31 | $6.7M | −$655,000 | −8.89% |
| 2017 | 2017-12-31 | $7.4M | $1.7M | +29.84% |
| 2016 | 2016-12-31 | $5.7M | $1.0M | +21.56% |
| 2015 | 2015-12-31 | $4.7M | $3.8M | +449.71% |
| 2014 | 2014-12-31 | $849,000 | −$1.4M | −61.43% |
| 2013 | 2013-12-31 | $2.2M | — | — |
NovoCure quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6.9M | $1.4M | +26.07% |
| Q1 2026 | 2026-03-31 | $5.2M | −$5.5M | −51.45% |
| Q4 2025 | 2025-12-31 | $4.9M | −$4.0M | −45.25% |
| Q3 2025 | 2025-09-30 | $5.7M | −$5.0M | −47.07% |
| Q2 2025 | 2025-06-30 | $5.5M | −$6.0M | −52.07% |
| Q1 2025 | 2025-03-31 | $10.6M | −$1.2M | −9.95% |
| Q4 2024 | 2024-12-31 | $8.9M | $2.1M | +31.10% |
| Q3 2024 | 2024-09-30 | $10.7M | $3.4M | +47.29% |
| Q2 2024 | 2024-06-30 | $11.4M | $4.5M | +65.14% |
| Q1 2024 | 2024-03-31 | $11.8M | $5.7M | +93.56% |
| Q4 2023 | 2023-12-31 | $6.8M | $390,000 | +6.06% |
| Q3 2023 | 2023-09-30 | $7.3M | $1.6M | +27.18% |
| Q2 2023 | 2023-06-30 | $6.9M | $2.8M | +67.78% |
| Q1 2023 | 2023-03-31 | $6.1M | $995,000 | +19.54% |
| Q4 2022 | 2022-12-31 | $6.4M | −$7.8M | −54.95% |
| Q3 2022 | 2022-09-30 | $5.7M | $2.4M | +72.98% |
| Q2 2022 | 2022-06-30 | $4.1M | $1.5M | +57.79% |
| Q1 2022 | 2022-03-31 | $5.1M | $1.1M | +27.93% |
| Q4 2021 | 2021-12-31 | $14.3M | $8.5M | +147.86% |
| Q3 2021 | 2021-09-30 | $3.3M | $515,000 | +18.51% |
| Q2 2021 | 2021-06-30 | $2.6M | −$697,000 | −21.03% |
| Q1 2021 | 2021-03-31 | $4.0M | $869,000 | +27.92% |
| Q4 2020 | 2020-12-31 | $5.8M | $2.7M | +88.51% |
| Q3 2020 | 2020-09-30 | $2.8M | $74,000 | +2.73% |
| Q2 2020 | 2020-06-30 | $3.3M | $918,000 | +38.30% |
| Q1 2020 | 2020-03-31 | $3.1M | $787,000 | +33.85% |
| Q4 2019 | 2019-12-31 | $3.1M | −$712,000 | −18.90% |
| Q3 2019 | 2019-09-30 | $2.7M | $1.4M | +100.15% |
| Q2 2019 | 2019-06-30 | $2.4M | $1.5M | +180.68% |
| Q1 2019 | 2019-03-31 | $2.3M | $1.6M | +215.47% |
| Q4 2018 | 2018-12-31 | $3.8M | −$1.6M | −30.43% |
| Q3 2018 | 2018-09-30 | $1.4M | $809,000 | +148.71% |
| Q2 2018 | 2018-06-30 | $854,000 | $478,000 | +127.13% |
| Q1 2018 | 2018-03-31 | $737,000 | −$294,000 | −28.52% |
| Q4 2017 | 2017-12-31 | $5.4M | $4.8M | +776.21% |
| Q3 2017 | 2017-09-30 | $544,000 | −$1.2M | −68.28% |
| Q2 2017 | 2017-06-30 | $376,000 | −$2.0M | −83.92% |
| Q1 2017 | 2017-03-31 | $1.0M | $29,000 | +2.89% |
| Q4 2016 | 2016-12-31 | $618,000 | −$436,000 | −41.37% |
| Q3 2016 | 2016-09-30 | $1.7M | $519,000 | +43.39% |
| Q2 2016 | 2016-06-30 | $2.3M | $530,000 | +29.31% |
| Q1 2016 | 2016-03-31 | $1.0M | $393,000 | +64.53% |
| Q4 2015 | 2015-12-31 | $1.1M | — | — |
| Q3 2015 | 2015-09-30 | $1.2M | — | — |
| Q2 2015 | 2015-06-30 | $1.8M | — | — |
| Q1 2015 | 2015-03-31 | $609,000 | — | — |
NovoCure capital expenditures (capex) trends
Over the last five fiscal years, NovoCure's capital expenditures (capex) increased from $15.0M to $26.6M, a change of $11.7M. The latest reported quarter, Q2 2026, shows $6.9M.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NovoCure source filings ↗